---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123366"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:45:57.029737+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MindMed Q3 net loss $13.7M; cash $295.3M; Phase 3 Voyage on track for Q4 2024

## Summary
- Net loss $13.7M vs $17.9M a year ago; R&D expenses $17.2M (up $4.0M YoY) on MM120/MM402 programs.
- Cash and equivalents $295.3M as of Sep 30, 2024; expected to fund operations into 2027.
- Phase 3 Voyage study of MM120 ODT in GAD to start Q4 2024; 12-week topline data expected H1 2026.
- Phase 3 Panorama (GAD) and Phase 3 Emerge (MDD) studies on track to initiate in H1 2025.
- Completed Phase 1 study of MM402 (R(-)-MDMA) for Autism Spectrum Disorder in October 2024.

## SEC filing metadata
- accession: 0000950170-24-123366
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017024123366/0000950170-24-123366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017024123366/mnmd-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123366
- JSON: https://secwatch.observer/filing/0000950170-24-123366.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.